For patienter behandlet med 600 mg, var de nuværende estimater for median progressionsfri overlevelse og overlevelse i det hele taget henholdsvis 22, 9 og 42, 5 måneder.
For the patients treated at 600 mg, the current estimates for median progression-free-survival and overall survival were 22.9 and 42.5 months, respectively.